Bavarian Nordic gains US contract for additional mpox vaccine
The vaccine bulk manufacturing is scheduled for 2025 with the delivery of the freeze-dried doses set for 2026.
Medscape7d
One Dose of MVA-BN Moderately Effective Against Mpox
In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...
News Medical on MSN9d
Single dose of MVA-BN vaccine offers 58% protection against mpox
The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...
HealthDay on MSN7d
One-Dose MVA-BN Vaccine Moderately Effective Against Mpox
One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in ...
Tehran Times10d
MVA-BN prequalified as first effective vaccine against mpox
The World Health Organization (WHO) has authorized the MVA-BN vaccine as the first vaccine against mpox to be added to its ...
cnbctv1812d
WHO approves Bavarian Nordic’s MVA-BN as first Mpox vaccine
A recent Canadian trial revealed that the vaccine, originally developed for smallpox, offers 58% protection against Mpox ...
India TV11d
WHO approves first Mpox vaccine for limited use in select countries
Image Source : AP/FILE PHOTO WHO approves the first Mpox vaccine for limited use in select countries. The World Health Organization (WHO) has approved the MVA-BN vaccine, developed by Bavarian ...